http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations
-
Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders
-
Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives
-
Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video Interview
-
Genprex to Present at the 2020 LD Micro Virtual Conference
-
Genprex to Present at the 2020 LD Micro Virtual Conference
-
Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants
-
Genprex (GNPX) Prices 5M Shares at $3.50
-
Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants
-
Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes
-
Genprex (GNPX) Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)
-
Genprex to Present at NobleCon16 Investor Conference
-
Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy
-
Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering
-
Genprex (GNPX) Prices 7.62M Share Common Offering at $1.05/Sh
-
Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market
-
Genprex (GNPX) Granted FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer
-
Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer
-
Genprex to Present at Biotech Showcase™ 2020 in San Francisco
-
Genprex (GNPX) Announces $1.26 Million Registered Direct Offering
-
Genprex Announces $1.26 Million Registered Direct Offering
-
Genprex (GNPX) Reports Positive Preclinical Data for Treatment of Some of the Most Resistant Metastatic Lung Cancers
-
Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers
-
Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month
-
Genprex to Present at the MicroCap Rodeo Investor Conference
-
Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support
-
Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment
-
Genprex (GNPX) Featured in Publication on Advances in Potential Breast Cancer Treatments
-
Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019
-
Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer
-
CORRECTING and REPLACING Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference
-
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatments
-
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatments
-
Genprex (GNPX) Featured in NetworkNewsWire Publication Summarizing Gene Therapy Treatment for Lung Cancer
-
Genprex (GNPX) Featured in NetworkNewsWire Publication Summarizing Gene Therapy Treatment for Lung Cancer
-
Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference
-
Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck
-
Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector
-
Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector
-
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Company’s Milestone Achievements
-
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Company’s Milestone Achievements
-
Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference
-
Genprex Demonstrates Growth and Expansion Through Recent Achievements
-
Genprex™ Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program
-
Genprex Begins Next Phase of Drug Branding Program
-
Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer
-
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment
-
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment

